BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BioNTech SENASDAQ: BNTX
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of €834.39M (cash outflow) rose 90.3% year over year, behind the +348.2% change in trailing-twelve-month net income. Sequentially, it rose 54.3% from the prior quarter.
Context
- Net income amounted to 39.6% of revenue in FY2025, up 15.0 pp from a year earlier.
- Net income increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -€1.37B (+26.0%) for the fiscal year ending Dec 2026, a slowdown from the +61.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -€834.39M+54.3% QoQ
- Last fiscal yearDec 2025
- -€1.09B+61.0% YoY
- LTMJun 2026
- -€1.71B+348.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +90.3% | +611.3% | +521.1 pp |
| 1 year | +61.0% | +26.0% | -35.0 pp |
| 3-year CAGR | — | -3.7% | — |
| 5-year CAGR | -13.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (1.09B) EUR
- Year-over-year change
- -61.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.09B) | -61.0% |
| FY2024 | 2024-12-31 | (677.7M) | -157.1% |
| FY2023 | 2023-12-31 | 1.19B | -90.8% |
| FY2022 | 2022-12-31 | 12.95B | -13.9% |
| FY2021 | 2021-12-31 | 15.05B | — |
Net Income vs competitors
How BNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +348.2% is the 2nd highest of 9, against a peer median of +27.4%.
- Net income amounts to 64.7% of revenue for BNTX, versus a peer median of 46.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Jun 2026 | $1.61B USD | +85.1% | +55.7% | 27.7% | |
| LTM Sep 2026 | $1.11B USD | +218.3% | -5.5% | 607.8% | |
| LTM Jun 2026 | $861.1M USD | — | -48.4% | 20.8% | |
| LTM Sep 2026 | $220.54M USD | -44.5% | -0.4% | 58.2% | |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Sep 2026 | $106.06M USD | -76.3% | — | 11.8% | |
| LTM Jun 2026 | $71.19M USD | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Dec 2025 | $35.34M USD | — | — | 48.6% | |
| LTM Mar 2026 | $27.59M USD | +28.8% | -20.5% | 7.2% | |
| Peer median (excluding BNTX) | — | +27.4% | -5.5% | 46.7% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.05B | 12.95B | 1.19B | (677.7M) | (1.09B) |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 70.98M |
| Stock-Based Compensation | 93.9M | 108.6M | 51.4M | 100.9M | 0 |
| Change in Working Capital | (10.73B) | 4.52B | 5.57B | 1.22B | 516.57M |
| Accounts Receivables | (11.81B) | 4.37B | 5.37B | 387.7M | 1.04B |
| Inventory | (438.4M) | 62.9M | 81.9M | 74.5M | 170.88M |
| Accounts Payables | 1.52B | 85.7M | 118.9M | 758.4M | (695.23M) |
| Other Working Capital | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | (3.6B) | (4.13B) | (1.62B) | (734.1M) | 574.01M |
| Operating Cash Flow | 889.7M | 13.58B | 5.37B | 207.7M | 438M |
| Capital Expenditures | (154M) | (363.3M) | (705.5M) | (452.3M) | (168.19M) |
| Acquisitions (Net) | (20.8M) | 0 | (336.9M) | 0 | 183.27M |
| Purchases of Investments | (394.7M) | (47.8M) | (6.98B) | (12.37B) | (10.97B) |
| Sales of Investments | 0 | 375.2M | 1.19B | 10.74B | 9.14B |
| Other Investing Activities | (23.1M) | (33.5M) | (576.59M) | (164.6M) | 0 |
| Investing Cash Flow | (566.1M) | (35.3M) | (6.95B) | (2.08B) | (2.37B) |
| Debt Repayment | (66.7M) | (59.1M) | (40.1M) | (45.9M) | (10.85M) |
| Common Stock Issued | 160.9M | 110.5M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (986.4M) | (738.5M) | 0 | 0 |
| Dividends Paid | 0 | (484.3M) | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (39.96M) |
| Financing Cash Flow | 94.2M | (1.42B) | (778.6M) | (45.9M) | (50.81M) |
| Effect of Forex Changes | 64.7M | 60.1M | 150.3M | 14.8M | 1.05B |
| Net Change in Cash | 482.5M | 12.18B | (2.21B) | (1.9B) | (931.17M) |
| Free Cash Flow | 735.7M | 13.21B | 4.67B | (244.6M) | 269.81M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.